Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(3)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07371013Not ApplicableNot Yet Recruiting

Fecal Microbiota Transplantation in Children With Autism Spectrum Disorder and Gastrointestinal Symptoms

Role: collaborator

NCT07094984Not ApplicableRecruiting

Comparison of Three Interventions for Antibiotic-Resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract

Role: collaborator

NCT05204641Phase 2Completed

Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease

Role: collaborator

NCT06156956Not ApplicableUnknown

Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol

Role: lead

NCT04824222Phase 3Unknown

The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters

Role: collaborator

All 5 trials loaded